FDA approves Capvaxive pneumococcal 21-valent conjugate vaccine
The U.S. Food and Drug Administration has approved Merck's Capvaxive pneumococcal 21-valent conjugate vaccine for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults.
Jun 24, 2024
0
1